Table 4.

Characteristics of LTBI studies that use QTF-G as part of a screening program in RA and other chronic inflammatory diseases.

StudyStudy GroupPositive QTF-G, %Positive TST, %Agreement, %Kappa*Patients, n
Matulis16RA, SpA, UA, otherNANA640.17109
Cobanoglu20Chronic inflammatory diseases1873NA0.1851
Takahashi21RA28.528.5NANA14
Greenberg17RA1821.3NANA61
Chen22RANANA600.2135
Ponce de Leon10RA44.626.770.30.37101
Bartalesi23Autoimmune diseases131987.70.55398
Bocchino24RA, PsA, UC, CD31.826NA0.2669
  • RA: rheumatoid arthritis; SpA: spondyloarthropathies; UA: undifferentiated arthritis; PsA: psoriatic arthritis; UC: ulcerative colitis; CD: Crohn’s disease; QTF-G: Quantiferon-TB Gold test; TST: tuberculin skin test.

  • * For agreement between QTF-G and TST. NA: not available.